Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: A dynamic mixer comprising two mixing parts which are rotatable relative to each other about a predetermined axis of rotation, each of said mixing parts having a mixing face, between which is defined a flow path which extends between an inlet and an outlet, each of said mixing faces comprising a series of annular steps centered on the predetermined axis of rotation, having a plurality of offset and overlapping cavities formed therein, such that material moving between the mixing faces of the two mixing parts from the inlet to the outlet is transferable between overlapping cavities.

Abstract: The present invention relates to the compound of formula (I) and to compositions comprising the same and to the use of the compound and to compositions of the compound in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compound.

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

Abstract: A distributive and dispersive mixing apparatus comprising two confronting surfaces (1,2) having cavities (3) therein which on relative motion of the surfaces function as a cavity transfer mixer (CTM) or controlled deformation dynamic mixer (CDDM) or both, CHARACTERISED IN THAT the normal separation of the confronting surfaces varies in the direction of bulk flow, so as to define a plurality of regions of successive closer and wider spacing of the confronting surfaces.

Abstract: CHO cell-specific synthetic promoter constructs for expressing recombinant proteins, a library of promoter constructs thereof, and a method for producing the promoter constructs. The promoter constructs enable precise control of recombinant gene transcription over three orders of magnitude, with the top expressing promoters capable of double the transcriptional activity of the CMV promoter.

Abstract: The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.

Abstract: A free-standing wall includes concrete base blocks adjacent to each other forming a base course; a first set of concrete wall blocks stacked on the base course and on each other to form a first wall face; and a second set of concrete wall blocks stacked on the base course and on each other to form a second wall face that faces the opposite direction from the first wall face and that has the same number of courses as the first plurality of wall blocks. Methods of constructing the wall arrangement include laying the base blocks next to each other end to end; stacking individual blocks of a first set of blocks on the base course and then on each other to form a first wall face; stacking individual blocks of the second set of blocks on the base course and then on each other to form a second wall face that faces a direction opposite of the first wall face.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: A method is presented for providing a Customer hosted chat invitation to a browsing user. A service provider provides a Customer with a set of interactive invitation input objects, and the Customer creates and stores a set of customized invitation setup data from interacting with the input objects. The service provider runs custom code to generate, from the set of customized invitation setup data, an invitation program code module characterized by a set of programmatic invitation criteria. The invitation program code module is connected to a web page creating program code that resides on a web server operatively associated with the Customer site so that the browsing user's choices can be monitored and stored and, when selected invitation criteria are met by these choices, an invitation event is triggered. System claims to related subject matter are also presented.

Abstract: A drivetrain assembly includes a transmission and a driveshaft that are joined together by a transmission flange and a driveshaft flange that has a plurality of pre-assembled bolts. The driveshaft flange defines a plurality of holes and countersink recesses and the bolts are secured to the driveshaft flange by a bolt retainer disposed in each of the countersink recesses between the transmission flange and the driveshaft flange. A method is disclosed for assembling a transmission flange and a driveshaft flange that defines a plurality of holes and countersink recesses. A bolt is assembled into each of the holes and countersink recesses and a bolt retainer is attached to each of the bolts and nested inside the countersink recesses to retain the bolts on the driveshaft flange. The bolts on the driveshaft flange are then installed into the threaded holes of the transmission flange.

Abstract: A radiotherapy system comprises a patient support, moveable along a translation axis, an imaging apparatus, comprising a first magnetic coil and a second magnetic coil, the first and second magnetic coils having a common central axis parallel to the translation axis, and being displaced from one another along the central axis to form a gap therebetween, the imaging apparatus being configured to obtain an image of a patient on the patient support, a source of radiation mounted on a chassis, the chassis being rotatable about the central axis and the source being adapted to emit a beam of radiation through the gap along a beam axis that intersects with the central axis, a multi-leaf collimator comprising a plurality of elongate leaves movable between at least a withdrawn position in which the leaf lies outside the beam, and an extended position in which the leaf projects across the beam, and a radiation detector mounted to the chassis opposite the source, the radiation detector having a plurality of detector ele

Abstract: Evacuation slide systems including a slide pack comprising a packboard coupled to an aircraft door, a girt bar coupled to an aircraft floor when the aircraft door is armed, and a restraint coupled to the packboard and the girt bar are detailed. The restraint controls a speed at which the aircraft door opens when the aircraft door is armed until the aircraft door has traveled beyond a predetermined distance.

Abstract: The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.

Abstract: An assembly and process for forming a two stage extrusion of an elongated marine dock from a plasticized material, such as including but act limited to extruding a first generally “L” shaped bracket from a first more rigid thermoplastic, following which a cross head die arrangement is utilized in order to extrude a secondary arcuate and flexible material in extending fashion from a lower side of the “L” bracket. The secondary/flexible elastomer is extracted in an open flexed position relative to the first extruded bracket, and further such that, following completion, can be flexed into a closed engagement with an upper perpendicularly extending side of the bracket.

Abstract: A free-standing wall includes concrete base blocks adjacent to each other forming a base course; a first set of concrete wall blocks stacked on the base course and on each other to form a first wall face; and a second set of concrete wall blocks stacked on the base course and on each other to form a second wall face that faces the opposite direction from the first wall face and that has the same number of courses as the first plurality of wall blocks. Methods of constructing the wall arrangement include laying the base blocks next to each other end to end; stacking individual blocks of a first set of blocks on the base course and then on each other to form a first wall face; stacking individual blocks of the second set of blocks on the base course and then on each other to form a second wall face that faces a direction opposite of the first wall face.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: The oligomerization of ethylene using a chromium catalyst having a heteroatomic ligand may be used to provide oligomerization products that are selective towards hexene and/or octene. However, such processes also typically produce some polymer as an undesirable by product. The present invention is directed towards improvements in the selective oligomerization of ethylene.

Abstract: This disclosure relates to films comprising at least one layer of an ethylene interpolymer product. The ethylene interpolymer product comprises a first ethylene interpolymer, a second ethylene interpolymer and optionally a third ethylene interpolymer; wherein the ethylene interpolymer product has ?0.03 terminal vinyl unsaturations per 100 carbon atoms and ?3 parts per million (ppm) of a total catalytic metal; and optionally a Dilution Index, Yd, greater than 0. The disclosed ethylene interpolymer products have a melt index from about 0.4 to about 10 dg/minute, a density from about 0.900 to about 0.940 g/cm3, a polydispersity (Mw/Mn) from about 2 to about 12 and a CDBI50 from about 20% to about 98%. Further, the ethylene interpolymer products are a blend of at least two ethylene interpolymers; where one ethylene interpolymer is produced with a single-site catalyst formulation and at least one ethylene interpolymer is produced with a heterogeneous catalyst formulation.